BIGBEAR
PHARMACEUTICAL
Repotrectinib potently and selectively inhibits the abnormally activated kinase signaling pathways of ROS1 and NTRK, effectively overcomes resistance mutations to conventional targeted therapies, and exhibits favorable central nervous system penetration.
AuthenticGuaranteeFast DeliveryPrivacy Repotrectinib, a targeted drug for ROS1-positive non-small cell lung cancer, provides relief, but its potential side effects require timely detection ···【More】
Update: 10 Mar,2026Source: BigbearViews: 88
Repotrectinib has demonstrated breakthrough therapeutic efficacy against specific gene-mutant lung cancers, providing an important treatment option fo···【More】
Update: 10 Mar,2026Source: BigbearViews: 89
Repotrectinib, a novel kinase inhibitor, offers a new treatment option for certain lung cancer patients. Understanding its indications, contraindicati···【More】
Update: 10 Mar,2026Source: BigbearViews: 87
On November 16, 2023, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved ripretinib (Augtyro) for the treatm···【More】
Update: 03 Mar,2026Source: BigbearViews: 91
Ripretinib (Augtyro) is a next-generation targeted anticancer drug developed by Bristol-Myers Squibb (BMS), offering a new precision treatment option ···【More】
Update: 03 Mar,2026Source: BigbearViews: 87
Repotrectinib is a novel, oral, small-molecule, multi-target tyrosine kinase inhibitor (TKI) primarily used to treat advanced solid tumors harboring s···【More】
Update: 03 Mar,2026Source: BigbearViews: 90
Repotrectinib, an innovative ROS1 and NTRK-targeting inhibitor, can simultaneously inhibit multiple oncogenic targets, exhibiting broad-spectrum anti-···【More】
Update: 03 Mar,2026Source: BigbearViews: 92
Repotrectinib is a new generation of targeted anticancer drug developed by Bristol-Myers Squibb (BMS), providing a new option for precision treatment ···【More】
Update: 03 Mar,2026Source: BigbearViews: 89
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
